Safety of Tranexamic Acid

Are Precautions Needed?

Research output: Contribution to journalArticle

Abstract

There are a numerous approaches to limit blood loss in orthopedic surgery, including meticulous surgical technique and hemostasis, use of tourniquets, hypotensive anesthesia, and pharmacologic methods such as tranexamic acid (TXA). TXA is an antifibrinolytic drug that has been found to effectively treat several bleeding-related conditions. It has also been used widely among surgical subspecialties because of its effects on hemostasis and ability to reduce transfusion rates. TXA is positively transforming blood management practices with respect to orthopedic surgery. The use of TXA in orthopedic surgery remains off-label use despite the numerous studies demonstrating the benefits of TXA in orthopedic patients. However, there are concerns over potential risks associated with the use of an antifibrinolytic agent during orthopedic surgery because of the inherent risk of thromboembolic events in the perioperative period. In this article, we review the use and safety of TXA in orthopedic surgery to guide clinical practice and blood product management. Complications and evidence for the contraindications of TXA administration are also examined to provide a clear picture of the risks and benefits of using TXA in orthopedic surgery patients.

Original languageEnglish (US)
Pages (from-to)28-33
Number of pages6
JournalTechniques in Orthopaedics
Volume32
Issue number1
DOIs
StatePublished - 2017

Fingerprint

Tranexamic Acid
Orthopedics
Safety
Antifibrinolytic Agents
Hemostasis
Off-Label Use
Tourniquets
Perioperative Period
Practice Management
Anesthesia
Hemorrhage

Keywords

  • antifibrinolytic
  • hemostasis
  • thromboembolic
  • tranexamic acid
  • transfusion

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Safety of Tranexamic Acid : Are Precautions Needed? / Kane, Ian W.; Naseer, Zan A.; Jones, Lynne C; Khanuja, Harpal S; Sterling, Robert Steven.

In: Techniques in Orthopaedics, Vol. 32, No. 1, 2017, p. 28-33.

Research output: Contribution to journalArticle

@article{23dde60fd41d4a2f84c392506a1771e2,
title = "Safety of Tranexamic Acid: Are Precautions Needed?",
abstract = "There are a numerous approaches to limit blood loss in orthopedic surgery, including meticulous surgical technique and hemostasis, use of tourniquets, hypotensive anesthesia, and pharmacologic methods such as tranexamic acid (TXA). TXA is an antifibrinolytic drug that has been found to effectively treat several bleeding-related conditions. It has also been used widely among surgical subspecialties because of its effects on hemostasis and ability to reduce transfusion rates. TXA is positively transforming blood management practices with respect to orthopedic surgery. The use of TXA in orthopedic surgery remains off-label use despite the numerous studies demonstrating the benefits of TXA in orthopedic patients. However, there are concerns over potential risks associated with the use of an antifibrinolytic agent during orthopedic surgery because of the inherent risk of thromboembolic events in the perioperative period. In this article, we review the use and safety of TXA in orthopedic surgery to guide clinical practice and blood product management. Complications and evidence for the contraindications of TXA administration are also examined to provide a clear picture of the risks and benefits of using TXA in orthopedic surgery patients.",
keywords = "antifibrinolytic, hemostasis, thromboembolic, tranexamic acid, transfusion",
author = "Kane, {Ian W.} and Naseer, {Zan A.} and Jones, {Lynne C} and Khanuja, {Harpal S} and Sterling, {Robert Steven}",
year = "2017",
doi = "10.1097/BTO.0000000000000206",
language = "English (US)",
volume = "32",
pages = "28--33",
journal = "Techniques in Orthopaedics",
issn = "0885-9698",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Safety of Tranexamic Acid

T2 - Are Precautions Needed?

AU - Kane, Ian W.

AU - Naseer, Zan A.

AU - Jones, Lynne C

AU - Khanuja, Harpal S

AU - Sterling, Robert Steven

PY - 2017

Y1 - 2017

N2 - There are a numerous approaches to limit blood loss in orthopedic surgery, including meticulous surgical technique and hemostasis, use of tourniquets, hypotensive anesthesia, and pharmacologic methods such as tranexamic acid (TXA). TXA is an antifibrinolytic drug that has been found to effectively treat several bleeding-related conditions. It has also been used widely among surgical subspecialties because of its effects on hemostasis and ability to reduce transfusion rates. TXA is positively transforming blood management practices with respect to orthopedic surgery. The use of TXA in orthopedic surgery remains off-label use despite the numerous studies demonstrating the benefits of TXA in orthopedic patients. However, there are concerns over potential risks associated with the use of an antifibrinolytic agent during orthopedic surgery because of the inherent risk of thromboembolic events in the perioperative period. In this article, we review the use and safety of TXA in orthopedic surgery to guide clinical practice and blood product management. Complications and evidence for the contraindications of TXA administration are also examined to provide a clear picture of the risks and benefits of using TXA in orthopedic surgery patients.

AB - There are a numerous approaches to limit blood loss in orthopedic surgery, including meticulous surgical technique and hemostasis, use of tourniquets, hypotensive anesthesia, and pharmacologic methods such as tranexamic acid (TXA). TXA is an antifibrinolytic drug that has been found to effectively treat several bleeding-related conditions. It has also been used widely among surgical subspecialties because of its effects on hemostasis and ability to reduce transfusion rates. TXA is positively transforming blood management practices with respect to orthopedic surgery. The use of TXA in orthopedic surgery remains off-label use despite the numerous studies demonstrating the benefits of TXA in orthopedic patients. However, there are concerns over potential risks associated with the use of an antifibrinolytic agent during orthopedic surgery because of the inherent risk of thromboembolic events in the perioperative period. In this article, we review the use and safety of TXA in orthopedic surgery to guide clinical practice and blood product management. Complications and evidence for the contraindications of TXA administration are also examined to provide a clear picture of the risks and benefits of using TXA in orthopedic surgery patients.

KW - antifibrinolytic

KW - hemostasis

KW - thromboembolic

KW - tranexamic acid

KW - transfusion

UR - http://www.scopus.com/inward/record.url?scp=85013391352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013391352&partnerID=8YFLogxK

U2 - 10.1097/BTO.0000000000000206

DO - 10.1097/BTO.0000000000000206

M3 - Article

VL - 32

SP - 28

EP - 33

JO - Techniques in Orthopaedics

JF - Techniques in Orthopaedics

SN - 0885-9698

IS - 1

ER -